Scynexis Initiates Phase 1 Study of SCY-770 to Treat Autosomal Dominant Polycystic Kidney Disease
MT Newswires Live
Jun 30
Scynexis (SCYX) said Tuesday that it has initiated a phase 1 study of SCY-770 to treat autosomal dominant polycystic kidney disease.
Autosomal dominant polycystic kidney disease can cause pain, high blood pressure and kidney failure in patients.
The biotech company said the study will characterize the food-effect and define the pharmacokinetics of two dosing regimens for SCY-770 to support dose selection for the phase 2 study, which it said is on track for Q4.
Topline data for the phase 1 study is expected to be released in Q3, according to Scynexis.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.